133 related articles for article (PubMed ID: 11369136)
1. Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.
Aszalos A; Ladányi A; Bocsi J; Szende B
Cancer Lett; 2001 Jun; 167(2):157-62. PubMed ID: 11369136
[TBL] [Abstract][Full Text] [Related]
2. Effect of combination of suboptimal concentrations of P-glycoprotein blockers on the proliferation of MDR1 gene expressing cells.
Hwang M; Ahn CH; Pine PS; Yin JJ; Hrycyna CA; Licht T; Aszalos A
Int J Cancer; 1996 Jan; 65(3):389-97. PubMed ID: 8575863
[TBL] [Abstract][Full Text] [Related]
3. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein.
Sikic BI; Fisher GA; Lum BL; Halsey J; Beketic-Oreskovic L; Chen G
Cancer Chemother Pharmacol; 1997; 40 Suppl():S13-9. PubMed ID: 9272128
[TBL] [Abstract][Full Text] [Related]
4. Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
Merlin JL; Bour-Dill C; Marchal S; Ramacci C; Poullain MG; Giroux B
Cytometry; 2000 Sep; 41(1):62-72. PubMed ID: 10942898
[TBL] [Abstract][Full Text] [Related]
5. Combinations of P-glycoprotein blockers, verapamil, PSC833, and cremophor act differently on the multidrug resistance associated protein (MRP) and on P-glycoprotein (Pgp).
Aszalos A; Thompson K; Yin JJ; Ross DD
Anticancer Res; 1999; 19(2A):1053-64. PubMed ID: 10368654
[TBL] [Abstract][Full Text] [Related]
6. Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Grey M; Borg AG; Wood P; Burgess R; Fisher A; Yin JA
Leuk Res; 1997 Sep; 21(9):867-74. PubMed ID: 9393602
[TBL] [Abstract][Full Text] [Related]
7. Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Didier A; Wenger J; Loor F
Anticancer Drugs; 1995 Oct; 6(5):669-80. PubMed ID: 8845477
[TBL] [Abstract][Full Text] [Related]
8. Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Lehne G; De Angelis P; den Boer M; Rugstad HE
Leukemia; 1999 May; 13(5):768-78. PubMed ID: 10374882
[TBL] [Abstract][Full Text] [Related]
9. Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Lehne G; Mørkrid L; den Boer M; Rugstad HE
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):187-95. PubMed ID: 10783828
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Pgp activity and cell cycle-dependent chemosensitivity to doxorubicin in the multidrug-resistant LoVo human colon cancer cell line.
Toffoli G; Corona G; Gigante M; Boiocchi M
Eur J Cancer; 1996 Aug; 32A(9):1591-7. PubMed ID: 8911123
[TBL] [Abstract][Full Text] [Related]
11. Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Merlin JL; Guerci AP; Marchal S; Bour C; Colosetti P; Kataki A; Guerci O
Br J Haematol; 1998 Nov; 103(2):480-7. PubMed ID: 9827923
[TBL] [Abstract][Full Text] [Related]
12. Multidrug resistance (MDR1) P-glycoprotein enhances esterification of plasma membrane cholesterol.
Luker GD; Nilsson KR; Covey DF; Piwnica-Worms D
J Biol Chem; 1999 Mar; 274(11):6979-91. PubMed ID: 10066752
[TBL] [Abstract][Full Text] [Related]
13. The solvents cremophor EL and Tween 80 modulate daunorubicin resistance in the multidrug resistant Ehrlich ascites tumor.
Friche E; Jensen PB; Sehested M; Demant EJ; Nissen NN
Cancer Commun; 1990; 2(9):297-303. PubMed ID: 1976341
[TBL] [Abstract][Full Text] [Related]
14. Cyclosporins: structure-activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter.
Loor F; Tiberghien F; Wenandy T; Didier A; Traber R
J Med Chem; 2002 Oct; 45(21):4598-612. PubMed ID: 12361387
[TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.
Lehne G; Rugstad HE
Br J Cancer; 1998 Sep; 78(5):593-600. PubMed ID: 9744497
[TBL] [Abstract][Full Text] [Related]
16. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Aouali N; El Btaouri H; Dumontet C; Eddabra L; Malagarie-Cazenave S; Madoulet C; Morjani H
Oncol Rep; 2011 Apr; 25(4):1161-7. PubMed ID: 21318225
[TBL] [Abstract][Full Text] [Related]
18. Purification and reconstitution of human P-glycoprotein.
Ambudkar SV; Lelong IH; Zhang J; Cardarelli C
Methods Enzymol; 1998; 292():492-504. PubMed ID: 9711577
[TBL] [Abstract][Full Text] [Related]
19. Influence of beta-adrenergic antagonists, H1-receptor blockers, analgesics, diuretics, and quinolone antibiotics on the cellular accumulation of the anticancer drug, daunorubicin: P-glycoprotein modulation.
Ibrahim S; Peggins J; Knapton A; Licht T; Aszalos A
Anticancer Res; 2001; 21(2A):847-56. PubMed ID: 11396174
[TBL] [Abstract][Full Text] [Related]
20. Cellular uptake and antiproliferative effects of therapeutic concentrations of idarubicin or daunorubicin and their alcohol metabolites, with or without cyclosporin A, in MDR1+ human leukemic cells.
Chiodini B; Bassan R; Barbui T
Leuk Lymphoma; 1999 May; 33(5-6):485-97. PubMed ID: 10342576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
